NCT04007224View on ClinicalTrials.gov

Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

June 28, 2023

Study Completion Date

July 10, 2023

Conditions
Autistic Spectrum Disorder
Interventions
DRUG

Intranasal oxytocin

daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd

BIOLOGICAL

Autologous umbilical cord blood

patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth

Trial Locations (2)

040245

Spitalul Angiomedica, Bucharest

Unknown

Medicover Hospital, Bucharest

All Listed Sponsors
collaborator

Spitalul Angiomedica

UNKNOWN

lead

Fundatia Bio-Forum

OTHER

NCT04007224 - Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder | Biotech Hunter | Biotech Hunter